Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
$133.64
+5.3%
$140.52
$123.00
$225.00
$3.74B1.25552,027 shs968,027 shs
NovoCure Limited stock logo
NVCR
NovoCure
$17.51
+3.7%
$17.65
$14.17
$34.13
$1.88B0.721.13 million shs1.36 million shs
Penumbra, Inc. stock logo
PEN
Penumbra
$247.67
-0.3%
$267.17
$148.00
$310.00
$9.62B0.47453,407 shs271,305 shs
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
$334.75
$332.85
$157.00
$334.90
$12.57B0.88968,088 shsN/A
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
+5.14%+2.25%-1.56%-12.89%-1.72%
NovoCure Limited stock logo
NVCR
NovoCure
+3.67%-2.07%+3.00%+3.30%+9.44%
Penumbra, Inc. stock logo
PEN
Penumbra
-0.15%-1.40%-4.31%-10.17%+38.15%
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
4.8288 of 5 stars
4.41.00.04.83.02.51.9
NovoCure Limited stock logo
NVCR
NovoCure
3.5856 of 5 stars
3.41.00.04.51.91.70.0
Penumbra, Inc. stock logo
PEN
Penumbra
4.6407 of 5 stars
3.43.00.03.72.72.51.9
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
2.73
Moderate Buy$211.9158.57% Upside
NovoCure Limited stock logo
NVCR
NovoCure
2.71
Moderate Buy$32.4385.20% Upside
Penumbra, Inc. stock logo
PEN
Penumbra
2.88
Moderate Buy$302.4022.10% Upside
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NVCR, PEN, INSP, and SWAV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
NovoCure Limited stock logo
NVCR
NovoCure
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
6/27/2025
NovoCure Limited stock logo
NVCR
NovoCure
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$34.00
5/6/2025
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$220.00 ➝ $200.00
5/6/2025
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$235.00 ➝ $195.00
5/6/2025
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$195.00 ➝ $174.00
5/6/2025
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$230.00 ➝ $236.00
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$320.00 ➝ $330.00
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$301.00 ➝ $318.00
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$315.00 ➝ $330.00
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$315.00 ➝ $330.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
$802.80M4.91$1.80 per share74.28$23.01 per share5.81
NovoCure Limited stock logo
NVCR
NovoCure
$605.22M3.23N/AN/A$3.33 per share5.26
Penumbra, Inc. stock logo
PEN
Penumbra
$1.19B8.03$2.88 per share86.04$29.99 per share8.26
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
$787.97M15.95$4.31 per share77.61$20.02 per share16.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
$53.51M$2.1761.5941.501.947.92%10.00%8.68%8/5/2025 (Estimated)
NovoCure Limited stock logo
NVCR
NovoCure
-$168.63M-$1.51N/AN/AN/A-26.41%-45.46%-13.34%7/24/2025 (Estimated)
Penumbra, Inc. stock logo
PEN
Penumbra
$14.01M$1.06233.6549.442.213.41%11.14%8.40%7/29/2025 (Estimated)
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
$147.28M$4.2878.2154.342.4320.75%24.79%11.95%N/A

Latest NVCR, PEN, INSP, and SWAV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
$0.22N/AN/AN/A$214.50 millionN/A
7/29/2025Q2 2025
Penumbra, Inc. stock logo
PEN
Penumbra
$0.81N/AN/AN/A$327.37 millionN/A
7/24/2025Q2 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.40N/AN/AN/A$153.87 millionN/A
5/5/2025Q1 2025
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
-$0.23$0.10+$0.33$0.10$194.89 million$201.32 million
4/24/2025Q1 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 million
4/23/2025Q1 2025
Penumbra, Inc. stock logo
PEN
Penumbra
$0.66$0.83+$0.17$1.00$315.72 million$324.14 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
N/AN/AN/AN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
N/A
9.01
7.44
NovoCure Limited stock logo
NVCR
NovoCure
0.27
1.47
1.41
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.30
3.68
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
0.97
13.81
12.61

Institutional Ownership

CompanyInstitutional Ownership
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
94.91%
NovoCure Limited stock logo
NVCR
NovoCure
84.61%
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
95.35%

Insider Ownership

CompanyInsider Ownership
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
2.30%
NovoCure Limited stock logo
NVCR
NovoCure
5.52%
Penumbra, Inc. stock logo
PEN
Penumbra
5.00%
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
3.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
1,24629.49 million28.82 millionOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,488111.49 million105.33 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
4,50038.73 million36.79 millionOptionable
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
1,46837.54 million36.27 millionOptionable

Recent News About These Companies

Johnson & Johnson completes $1.7B V-Wave acquisition
Shockwave E8 Peripheral IVL Catheter Launched
Baird Q2 2024 Small/Mid Cap Growth Equity Fund Commentary

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Inspire Medical Systems stock logo

Inspire Medical Systems NYSE:INSP

$133.64 +6.73 (+5.30%)
Closing price 07/8/2025 03:59 PM Eastern
Extended Trading
$133.47 -0.17 (-0.13%)
As of 05:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

NovoCure stock logo

NovoCure NASDAQ:NVCR

$17.51 +0.62 (+3.67%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$17.66 +0.15 (+0.86%)
As of 07/8/2025 06:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Penumbra stock logo

Penumbra NYSE:PEN

$247.67 -0.70 (-0.28%)
Closing price 07/8/2025 03:59 PM Eastern
Extended Trading
$250.00 +2.33 (+0.94%)
As of 07/8/2025 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Shockwave Medical stock logo

Shockwave Medical NASDAQ:SWAV

Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.